BIOCRYST PHARMACEUTICALS, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 172.0% | -632.6% | -31.3% |
| FY2022 | 83.9% | 392.4% | -44.9% |
| FY2023 | 49.7% | 148.7% | -43.8% |
| FY2024 | 18.7% | 55.2% | -18.1% |
| FY2025 | -221.4% | -221.4% | 51.3% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 172.0% | -632.6% | -31.3% |
| FY2022 | 83.9% | 392.4% | -44.9% |
| FY2023 | 49.7% | 148.7% | -43.8% |
| FY2024 | 18.7% | 55.2% | -18.1% |
| FY2025 | -221.4% | -221.4% | 51.3% |